Terry-Ann Burrell - Jul 12, 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role: Director
Signature: /s/ Jonathan Golightly, attorney-in-fact
Stock symbol: RXRX
Transactions as of: Jul 12, 2023
Transactions value $: -$1,412,414
Form type: 4
Date filed: 7/14/2023, 06:52 PM
Previous filing: Jun 21, 2023
Next filing: Feb 2, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	RXRX	Class A Common Stock	Sale	-$273K	-24.3K	-14.14%	$11.25	148K	Jul 12, 2023	Direct	F1, F2
transaction	RXRX	Class A Common Stock	Sale	-$948K	-78.1K	-52.91%	$12.15	69.5K	Jul 12, 2023	Direct	F1, F3
transaction	RXRX	Class A Common Stock	Sale	-$42.1K	-3.2K	-4.6%	$13.18	66.3K	Jul 12, 2023	Direct	F1, F4
transaction	RXRX	Class A Common Stock	Sale	-$44.5K	-3.16K	-4.76%	$14.08	63.1K	Jul 12, 2023	Direct	F1, F5
transaction	RXRX	Class A Common Stock	Sale	-$104K	-8.28K	-13.11%	$12.59	54.8K	Jul 13, 2023	Direct	F1, F6

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Sales are pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 18, 2022.
F2	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $10.60 to $11.59 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F3	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $11.60 to $12.54 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F4	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.76 to $13.72 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F5	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $13.81 to $14.56 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.
F6	The sales price reported herein is a weighted average price. These shares were sold in multiple lots at prices ranging from $12.105 to $12.98 per share. Full sale price information for each lot is available to the Issuer's stockholders and the staff of the U.S. Securities and Exchange Commission upon their written request.